Nascent Biotech Stock Buy Hold or Sell Recommendation
| NBIO Stock | USD 0.06 0.0002 0.32% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Nascent Biotech is 'Strong Sell'. The recommendation algorithm takes into account all of Nascent Biotech's available fundamental, technical, and predictive indicators you will find on this site.
Check out Nascent Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Nascent and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Nascent Biotech. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Nascent |
Execute Nascent Biotech Buy or Sell Advice
The Nascent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nascent Biotech. Macroaxis does not own or have any residual interests in Nascent Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nascent Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Nascent Biotech Trading Alerts and Improvement Suggestions
| Nascent Biotech is way too risky over 90 days horizon | |
| Nascent Biotech has some characteristics of a very speculative penny stock | |
| Nascent Biotech appears to be risky and price may revert if volatility continues | |
| Nascent Biotech currently holds 64.89 K in liabilities. Nascent Biotech has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nascent Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Nascent Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nascent Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nascent to invest in growth at high rates of return. When we think about Nascent Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1000 K. Net Loss for the year was (470.39 K) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| About 32.0% of the company outstanding shares are owned by corporate insiders |
Nascent Biotech Returns Distribution Density
The distribution of Nascent Biotech's historical returns is an attempt to chart the uncertainty of Nascent Biotech's future price movements. The chart of the probability distribution of Nascent Biotech daily returns describes the distribution of returns around its average expected value. We use Nascent Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nascent Biotech returns is essential to provide solid investment advice for Nascent Biotech.
| Mean Return | 1.04 | Value At Risk | -15.82 | Potential Upside | 21.35 | Standard Deviation | 11.42 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nascent Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nascent Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nascent Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nascent Biotech's price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nascent otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.82 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 11.50 | |
Ir | Information ratio | 0.08 |
Nascent Biotech Volatility Alert
Nascent Biotech is showing large volatility of returns over the selected time horizon. Nascent Biotech is a penny stock. Although Nascent Biotech may be in fact a good investment, many penny otc stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Nascent Biotech. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Nascent instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Nascent Biotech Fundamentals Vs Peers
Comparing Nascent Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nascent Biotech's direct or indirect competition across all of the common fundamentals between Nascent Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nascent Biotech or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nascent Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Nascent Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nascent Biotech to competition |
| Fundamentals | Nascent Biotech | Peer Average |
| Return On Asset | -0.88 | -0.14 |
| Profit Margin | (1.25) % | (1.27) % |
| Operating Margin | (0.92) % | (5.51) % |
| Current Valuation | 21.83 M | 16.62 B |
| Shares Outstanding | 119.56 M | 571.82 M |
| Shares Owned By Insiders | 31.85 % | 10.09 % |
| Shares Owned By Institutions | 0.80 % | 39.21 % |
| Price To Earning | 66.00 X | 28.72 X |
| Price To Book | 6.91 X | 9.51 X |
| Price To Sales | 21.78 X | 11.42 X |
| Revenue | 1000 K | 9.43 B |
| Gross Profit | 1000 K | 27.38 B |
| EBITDA | (134.37 K) | 3.9 B |
| Net Income | (470.39 K) | 570.98 M |
| Cash And Equivalents | 145.57 K | 2.7 B |
| Total Debt | 64.89 K | 5.32 B |
| Debt To Equity | (1.89) % | 48.70 % |
| Current Ratio | 0.11 X | 2.16 X |
| Book Value Per Share | (0.01) X | 1.93 K |
| Cash Flow From Operations | 413.48 K | 971.22 M |
| Earnings Per Share | (0) X | 3.12 X |
| Number Of Employees | 5 | 18.84 K |
| Beta | -3.14 | -0.15 |
| Market Capitalization | 10.76 M | 19.03 B |
| Total Asset | 105.41 K | 29.47 B |
| Retained Earnings | (17.28 M) | 9.33 B |
| Working Capital | 383 K | 1.48 B |
| Current Asset | 522 K | 9.34 B |
| Current Liabilities | 139 K | 7.9 B |
| Net Asset | 105.41 K |
Nascent Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nascent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.17 | |||
| Daily Balance Of Power | (0.02) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.0564 | |||
| Day Typical Price | 0.0582 | |||
| Market Facilitation Index | 0.0108 | |||
| Price Action Indicator | 0.0053 | |||
| Period Momentum Indicator | (0.0002) |
About Nascent Biotech Buy or Sell Advice
When is the right time to buy or sell Nascent Biotech? Buying financial instruments such as Nascent OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nascent Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.